Teleflex (TFX) Downgraded by TheStreet to “C+”
Teleflex (NYSE:TFX) was downgraded by TheStreet from an “a-” rating to a “c+” rating in a note issued to investors on Monday.
Several other analysts have also recently commented on the stock. ValuEngine cut shares of Teleflex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Leerink Swann decreased their price objective on shares of Teleflex from $321.00 to $300.00 and set an “outperform” rating for the company in a research note on Friday, February 23rd. Stephens restated a “buy” rating and set a $300.00 price objective on shares of Teleflex in a research note on Thursday, January 18th. Finally, Deutsche Bank cut shares of Teleflex from a “buy” rating to a “hold” rating and set a $251.00 price objective for the company. in a research note on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company’s stock. Teleflex currently has a consensus rating of “Hold” and a consensus target price of $281.56.
Shares of Teleflex (NYSE:TFX) opened at $267.35 on Monday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.51 and a current ratio of 2.33. Teleflex has a 12 month low of $191.04 and a 12 month high of $288.78. The company has a market cap of $12,000.22, a P/E ratio of 81.76, a price-to-earnings-growth ratio of 1.96 and a beta of 1.22.
In related news, VP John Deren sold 1,359 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $255.67, for a total value of $347,455.53. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director George Babich, Jr. sold 2,500 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $283.11, for a total transaction of $707,775.00. Following the completion of the transaction, the director now owns 9,581 shares of the company’s stock, valued at $2,712,476.91. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,259 shares of company stock valued at $3,760,536. Company insiders own 2.39% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. increased its holdings in Teleflex by 24.1% in the 4th quarter. American Century Companies Inc. now owns 1,474,609 shares of the medical technology company’s stock worth $366,912,000 after acquiring an additional 286,700 shares in the last quarter. William Blair Investment Management LLC purchased a new stake in Teleflex in the 4th quarter worth $53,163,000. Renaissance Technologies LLC increased its holdings in Teleflex by 511.6% in the 4th quarter. Renaissance Technologies LLC now owns 195,700 shares of the medical technology company’s stock worth $48,694,000 after acquiring an additional 163,700 shares in the last quarter. BlackRock Inc. increased its holdings in Teleflex by 3.4% in the 4th quarter. BlackRock Inc. now owns 4,709,341 shares of the medical technology company’s stock worth $1,171,779,000 after acquiring an additional 156,527 shares in the last quarter. Finally, Redmile Group LLC increased its holdings in Teleflex by 449.9% in the 4th quarter. Redmile Group LLC now owns 172,486 shares of the medical technology company’s stock worth $42,918,000 after acquiring an additional 141,121 shares in the last quarter. Hedge funds and other institutional investors own 90.75% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Teleflex (TFX) Downgraded by TheStreet to “C+”” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/03/14/teleflex-tfx-downgraded-by-thestreet-to-c.html.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.